Zenios Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Zenios bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Zenios Bioscience Today - Breaking & Trending Today

Yaqrit Discovery Ltd: Preliminary results from Carbalive and Dialive trials signal potential for new therapies to treat decompensated cirrhosis and reverse liver failure

Yaqrit Discovery Ltd: Preliminary results from Carbalive and Dialive trials signal potential for new therapies to treat decompensated cirrhosis and reverse liver failure
Orally-administered,
non-absorbable engineered carbon, Carbalive
, was safe, tolerable and showed trends in improvements in a range of biomarkers of systemic inflammation associated with decompensated cirrhosis
Safety of novel dual filtration system, Dialive
, confirmed with liver failure patients more likely to see organ failure resolved and more quickly than control group
London, UK, 7 January 2021 - Yaqrit, a clinical stage life sciences company focused on developing potentially innovative treatments for patients with advanced liver disease in areas of high unmet medical need, today announces preliminary results from its randomised controlled clinical trials for two potential therapies from its pipeline of product candidates designed to address each stage of liver disease, from diagnos ....

United Kingdom , City Of , David Daley , Rajiv Jalan , Amber Fennell , Nathan Davies , Angela Gray , Akaza Bioscience , Zenios Bioscience , Jane Macnaughtan , European Union Horizon , Business Ltd , University College London Hospitals , London Global University , Liver Failure Group , Consilium Strategic Communications , Liver Failure , Professor Rajiv Jalan , European Foundation , Chronic Liver Failure , European Association , Project Coordinator , Professor Nathan Davies , Chief Executive Officer , European Union , Global Burden ,

Investegate |Yaqrit Discovery Ltd Announcements | Yaqrit Discovery Ltd: Preliminary results from Carbalive and Dialive trials signal potential for new therapies to treat decompensated cirrhosis and reverse liver failure

Yaqrit Discovery Ltd
Preliminary results from Carbalive and Dialive trials signal potential for new therapies to treat decompensated cirrhosis and reverse liver failure
Preliminary results from Carbalive and Dialive trials signal potential for new therapies to treat decompensated cirrhosis and reverse liver failure
Preliminary results from Carbalive and Dialive trials signal potential for new therapies to treat decompensated cirrhosis and reverse liver failure
Orally-administered,
non-absorbable engineered carbon, Carbalive
™, was safe, tolerable and showed trends in improvements in a range of biomarkers of systemic inflammation associated with decompensated cirrhosis
Safety of novel dual filtration system, Dialive
™, confirmed with liver failure patients more likely to see organ failure resolved and more quickly than control group ....

United Kingdom , City Of , David Daley , Rajiv Jalan , Amber Fennell , Nathan Davies , Angela Gray , Akaza Bioscience , Zenios Bioscience , Jane Macnaughtan , European Union Horizon , Business Ltd , University College London Hospitals , London Global University , Liver Failure Group , Portico Ventures Programme , Consilium Strategic Communications , Liver Failure , Professor Rajiv Jalan , European Foundation , Chronic Liver Failure , European Association , Project Coordinator , Professor Nathan Davies , Chief Executive Officer , European Union ,

The ALIVER Consortium announces positive results from Phase 2 equivalent trial of the novel liver dialysis device, Dialive

The ALIVER Consortium announces positive results from Phase 2 equivalent trial of the novel liver dialysis device, Dialive
Safety of novel liver dialysis device confirmed
Liver failure patients in ICU treated with Dialive more likely to see organ failure resolved, and more quickly (p=0.03)
Significant improvements in mechanistic biomarkers of how Dialive improves organ function
7
th January 2021 - The
ALIVER Consortiumis pleased to announce positive data from the randomised controlled clinical trial of Dialive in adult patients with liver failure. The study found that twice as many patients with a history indicative of alcohol-related cirrhosis suffering from multiorgan failure, a condition referred to as acute-on-chronic liver failure (ACLF), recovered to having no organ failure when treated with the Dialive device compared to the control group. ....

Rafael Ba , Rajiv Jalan , Amber Fennell , Banwari Agarwal , Universitario Gregorio Mara , Nathan Davies , Akaza Bioscience , Zenios Bioscience , Kostenloser Wertpapierhandel , Luniversidad Complutense , University College London , European Union Horizon , School Of Medicine , Liver Failure Group , Yaqrit Ltd , Consilium Strategic Communications , Professor Rajiv Jalan , Professor Nathan Davies , Founding Member , Consultant Intensivist , Royal Free Hospital , Chief Investigator , Chronic Liver Failure , Hospital General Universitario Gregorio Mara , European Union , Takeda Pharmaceutical ,

Carbalive: The CARBALIVE Consortium announces positive results of a Phase 2 equivalent trial of engineered macroporous carbons as a novel treatment for cirrhosis

(2)
The CARBALIVE Consortium announces positive results of a Phase 2 equivalent trial of engineered macroporous carbons as a novel treatment for cirrhosis
Patients treated with orally-administered, non-absorbable engineered carbon of controlled porosity was safe, tolerable and showed trends in improvements in a range of biomarkers of systemic inflammation
The mechanism of this effect is modulation of dysbiosis, gut inflammation and leaky gut that are characteristic of cirrhosis
Planning for pivotal trials to support approval in Europe is now under way
7
th January, 2021 - The
CARBALIVE Consortium( CARBALIVE or the Consortium ) is pleased to announce positive data from the Phase 2 equivalent randomised, double-blind clinical trial of Carbalive, a product candidate for the treatment of patients with decompensated cirrhosis. Carbalive is specifically designed to remove harmful bacterial toxins from the gut, reduce gut inflammation and its permeabilit ....

Rajiv Jalan , Amber Fennell , Universitario Ram , Agustin Albillos , Akaza Bioscience , Zenios Bioscience , Jane Macnaughtan , Kostenloser Wertpapierhandel , University College London , European Union Horizon , Liver Failure Group At University College London , Cajal Institute For Health , Digestive Diseases Group , Carbalive Consortium , Consilium Strategic Communications , European Foundation , Chronic Liver Failure , European Union , Professor Rajiv Jalan , Liver Failure Group , Founding Member , Project Coordinator , Hospital Universitario Ram , Universidad De Alcal , Cajal Institute , Takeda Pharmaceutical ,